Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex
References (52)
- et al.
Demonstration of a functional receptor for vasoactive intestinal polypeptide on Molt 4b T lymphoblasts
Regul. Pept.
(1983) - et al.
Interaction of vasoactive intestinal peptide (VIP) with rat lymphoid cells
Peptides
(1986) - et al.
Distribution of neuropeptide Y, vasoactive intestinal peptide and somatostatin in populations of postganglionic neurons innervating the rat kidney, spleen and intestine
Neurosci.
(1992) - et al.
Single step method of isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Anal. Biochem.
(1987) - et al.
Multiple neuropeptdes in nerves supplying mammalian lymph nodes: messenger candidates for sensory and autonomic neurotransmission
Neurosci. Lett.
(1988) - et al.
Vasoactive intestinal peptide downregulates the expression of IL-2 but not of IFNγ from stimulated murine T lymphocytes
J. Neuroimmunol.
(1993) - et al.
Demonstration of immunoreactive vasoactive intestinal peptide (IR-VIP) and somatostatin (IR-SOM) in rat thymus
Brain, Behav. Immun.
(1990) - et al.
Interaction of vasoactive intestinal peptide with human blood mononuclear cells
Mol. Cell. Endocrinol.
(1981) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxocity assays
J. Immunol. Methods
(1983)- et al.
The neuroimmune link in the bronchus-associated lymphoid tissue (BALT) of cat and rat: peptides and neural markers
Brain Behav. Immun.
(1991)
Vasoactive intestinal peptide-containing nerves in Peyer's patches
Brain Behav. Immun.
Induction of T-cell proliferation by recombinant mouse and chimeric mouse/human anti-CD3 monoclonal antibodies
Res. Immunol.
Variable stimulation of adenylate cyclase activity by vasoactive intestinal-like peptide and β-adrenergic agonist in murine T-cell lymphomas of immature, helper, and cytotoxic types
Immunobiology
CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxis. Relationship to vasoactive intestinal peptide
FEBS Lett.
Stimulatory effect of vasoactive intestinal peptide (VIP) on cyclic AMP production in rat peritoneal macrophages
Regul. Prpt.
An improved colorimetric assay for interleukin 2
J. Immunol. Methods
Inhibition of anti-CD3-induced T cell proliferation by crosslinking of stimulatory antibodies in the presence of PMA and interleukin 2
Cell. Immunol.
Binding of vasoactive intestinal peptide (VIP) by human blood monocytes: demonstration of specific binding sites
Regul. Pept.
Covalent cross-linking of vasoactive intestinal polypeptide to its receptors on intact human lymphoblasts
J. Biol. Chem.
Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2Rα gene expression at multiple levels
J. Immunol.
Dual effects of vasoactive intestinal peptide (VIP) on leucocyte migration
Acta Physiol. Scand.
Inhibition of mouse T cell proliferation by CGRP and VIP: effects of these neuropeptides on IL-2 production and cAMP synthesis
J. Neurosci. Res.
IL 2, 4 and 5 are sequentially produced in mitogen-stimulated murine spleen cell cultures
Eur. J. Immunol.
Specific binding sites for vasoactive intestinal peptide on nonadherent peripheral blood lymphocytes
J. Immunol.
Inhibition of cytokine production by cyclosporin A and transforming growth factor β
J. Exp. Med.
Noradrenergic and peptidergic innervation of lymphoid tissue
J. Immunol.
Cited by (82)
Characterization and use of a rabbit-anti-mouse VPAC1 antibody by flow cytometry
2012, Journal of Immunological MethodsCitation Excerpt :A functional example would be T cell homing to Peyer's Patches, as a lowering of VIP binding sites after mouse CD4 T cell activation is associated with reduced T cell homing (Ottaway, 1984). In addition, it has been shown that VPAC1 signaling can suppress the activation of CD4 T cells by inhibiting IL-2 and IL-4 expression thereby bolstering the T cell activation threshold and inhibiting bystander T cell activation (Sun and Ganea, 1993). Also, regulatory T cells (CD4+/CD25+/FOXP3+) have been shown to be enhanced by VIP/VPAC1 signal transduction.
TCR signaling and environment affect vasoactive intestinal peptide receptor-1 (VPAC-1) expression in primary mouse CD4 T cells
2008, Brain, Behavior, and ImmunityCitation Excerpt :In contrast, 5 ng/ml PMA and 1 μg/ml ionomycin showed a robust increase in IL-2 secretion (1476 pg/ml, n = 2) confirming that these naïve CD4 T cells can be appropriately activated (Fig. 1b). Anti-CD3 ± anti-CD28 treatment resulted in significantly elevated IL-2 levels (120 and 250 pg/ml, respectively; n = 5) and indicates that this ex vivo treatment successfully triggers TCR signaling and IL-2 secretion (Sun and Ganea, 1993; Schillace et al., 2005). To confirm the accuracy and precision of our qPCR procedure, we quantitated VPAC-1 mRNA levels from eleven different mouse tissues.
Morphological relationships between peptidergic nerve fibers and immunoglobulin A-producing lymphocytes in the mouse intestine
2008, Brain, Behavior, and ImmunityCitation Excerpt :VIP receptors are expressed not only on the IgA lymphocytes, but also on the T cells in the epithelium and the LP of the intestine (Qian et al., 2001). On the other hand, VIP inhibits IL-2 and IL-10 production in T cells (Sun and Ganea, 1993; Martinez et al., 1996; Wang et al., 1996), whereas it promotes the production of IL-5 and IFN-γ (Mathew et al., 1992; Jabrane-Ferrat et al., 1999), and increases mRNA levels of IL-8 to increase secretion (Toumi et al., 2004). Therefore, it is possible that neuropeptides liberated from varicosities regulate IgA synthesis in lymphocytes via T cell activity.
α-Helical structure in the C-terminus of vasoactive intestinal peptide: Functional and structural consequences
2004, European Journal of Pharmacology
- #
In partial fulfilment of the requirements for the degree of Doctor in Philosophy in the Graduate College, Rutgers University, Newark, NJ 07102, USA.